Lokivetmab
| Lokivetmab | ||
|---|---|---|
| Secondary to quaternary structure | Heterotetramer | |
| Identifier | ||
| External IDs |
|
|
| Drug information | ||
| ATC code | Q D11AH91 | |
| Drug class | Monoclonal antibodies | |
Lokivetmab (trade name Cytopoint , manufacturer Zoetis ) is a monoclonal antibody against canine interleukin 31 that is used in domestic dogs to treat atopic dermatitis . The active ingredient has been approved in the United States since 2015 and in the EU since 2017 and is injected subcutaneously once a month . A placebo-controlled double-blind study was able to demonstrate an improvement in the clinical picture and a significant reduction in itching, which was superior to the use of ciclosporin . Since the antibody is subject to normal protein breakdown, it can also be used in animals with liver or kidney damage. No side effects were clinically detectable.
Individual evidence
- ↑ Cytopoint on the European Medicines Agency website.
- ↑ Hilde Moyaert et al .: A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. In: Vet. Dermatology , September 2017 doi : 10.1111 / vde.12478